Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 25INDUSTRY 9NETWORK 2OTHER_GOV 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Specimen Handling 283Magnetic Resonance Spectroscopy 194Biopsy 163Nivolumab 42pembrolizumab 36Radiation 36Cyclophosphamide 35X-Rays 34Immunoglobulin G 34Disulfides 34Cisplatin 32Taxes 31Paclitaxel 31Platinum 301,2-diaminocyclohexaneplatinum II citrate 30Radiotherapy 29Carboplatin 29Doxorubicin 28atezolizumab 24Gemcitabine 24venetoclax 21Bevacizumab 20olaparib 18fludarabine 18Ipilimumab 18CTLA-4 Antigen 18cabozantinib 17Vincristine 17Prednisone 16Dexamethasone 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Drug Therapy × 30 days × Clear all
NCT07391774 2026-05-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
1,978 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡